Aditya Birla SL Pharma & Healthcare Fund (IDCW)

Aditya Birla SL Pharma & Healthcare Fund (IDCW)- Performance(%)

* returns above 1 yr. are annualized

	1w	1m	3m	6m	1y	3y	5y	Since INC
Scheme Returns	-2.01	-2.55	-1.42	18.83	51.73	13.61		21.93
Category Avg	-2.39	-2.84	-0.60	19.29	47.71	14.58	23.76	18.45
Category Best	0.31	-0.38	2.08	23.32	53.20	17.92	28.37	32.64
Category Worst	-2.01	-2.55	-1.42	18.83	51.73	13.61		21.93

	Dividends	Bonus
Ratio	11.78	0.00
Date	20-09-2023	20-09-2023

Fund Holdings

Asset Type	Instrument Name	Industry	Net Assets(%)	No of Shares	Mkt Value(Cr.)
Equity & Equity related Investments
Equity	Sun Pharma.Inds.	Pharmaceuticals & Biotechnology	14.84	6,86,256.00	103.08
Equity	Cipla	Pharmaceuticals & Biotechnology	7.83	3,88,342.00	54.37
Equity	Torrent Pharma.	Pharmaceuticals & Biotechnology	7.41	1,94,696.00	51.45
Equity	Apollo Hospitals	Healthcare Services	6.33	73,936.00	43.97
Equity	Fortis Health.	Healthcare Services	4.59	7,27,564.00	31.91
Equity	Zydus Lifesci.	Pharmaceuticals & Biotechnology	4.25	3,09,792.00	29.54
Equity	Ajanta Pharma	Pharmaceuticals & Biotechnology	4.16	1,30,419.00	28.89
Equity	Aurobindo Pharma	Pharmaceuticals & Biotechnology	4.01	2,41,254.00	27.83
Equity	Lupin	Pharmaceuticals & Biotechnology	3.89	1,64,214.00	27.03
Equity	Gland Pharma	Pharmaceuticals & Biotechnology	3.85	1,56,128.00	26.72
Equity	Alkem Lab	Pharmaceuticals & Biotechnology	3.46	49,770.00	24.05
Equity	Alembic Pharma	Pharmaceuticals & Biotechnology	3.46	2,40,291.00	24.02
Equity	J B Chem & Pharm	Pharmaceuticals & Biotechnology	3.37	1,22,938.00	23.42
Equity	Abbott India	Pharmaceuticals & Biotechnology	3.04	7,994.00	21.14
Equity	Dr Reddy's Labs	Pharmaceuticals & Biotechnology	2.84	31,795.00	19.73
Equity	Sanofi India	Pharmaceuticals & Biotechnology	2.75	22,949.00	19.11
Equity	Strides Pharma	Pharmaceuticals & Biotechnology	2.62	2,02,997.00	18.19
Equity	Jupiter Life Lin	Healthcare Services	2.34	1,31,408.00	16.22
Equity	Vijaya Diagnost.	Healthcare Services	2.23	2,20,987.00	15.45
Equity	Star Health Insu	Insurance	2.01	2,44,444.00	13.97
Equity	Mankind Pharma	Pharmaceuticals & Biotechnology	1.53	44,835.00	10.60
Equity	Medi Assist Ser.	Insurance	1.05	1,43,535.00	7.32
Equity	Granules India	Pharmaceuticals & Biotechnology	0.90	1,47,600.00	6.25
Equity	ERIS Lifescience	Pharmaceuticals & Biotechnology	0.86	66,534.00	5.96
Equity	Biocon	Pharmaceuticals & Biotechnology	0.64	1,48,818.00	4.44
Equity	Medplus Health	Retailing	0.57	56,620.00	3.95
Equity	Vinati Organics	Chemicals & Petrochemicals	0.45	18,952.00	3.10
Cash & Cash Equivalent
Reverse Repo	C C I	-/-	4.86	0.00	33.78
Net CA & Others	Net CA & Others	-/-	-0.14	0.00	-0.99

ATTENTION INVESTORS

Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

Risk Disclosure on Derivatives

9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
On an average, loss makers registered net trading loss close to Rs. 50,000.
Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

We are ISO 27001:2013 Certified.

This certificate demonstrates that IIFL as an organization has defined and put in place best-practice information security processes.